Towards a Chlamydia vaccine for males: The key role of mucosal IgA

Funding Activity

Website
http://grants.uberresearch.com/501100000925/http://purl.org/au-research/grants/nhmrc/553055/Towards-a-Chlamydia-vaccine-for-males-The-key-role-of-mucosal-IgA

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Genital Chlamydia infections are the most common sexually transmitted infection in Australia with annual health costs of 90-160 million dollars. Infection rates in 15-29 olds are increasing at 15-20% per year in both females and males. Antibiotics are currently the treatment of choice, however antibiotic resistance is increasing and most infections are asymptomatic and not treated in the absence of screening programs. This project aims to develop a Chlamydia vaccine tailored to protect males .

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2012

Funding Scheme: NHMRC Project Grants

Funding Amount: $418,978.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Chlamydia | Immunisation | Immunoglobulin (IgA) | Infectious Diseases | Male Infertility | Mens Reproductive Health | Mucosal Immunity | Sexually Transmitted Infections | Vaccines

Related Links